Inflammation: a Good Research Target to Improve Outcomes of Poor-Grade Subarachnoid Hemorrhage

Hidenori Suzuki
DOI: https://doi.org/10.1007/s12975-019-00713-y
2019-06-18
Translational Stroke Research
Abstract:Aneurysmal subarachnoid hemorrhage (SAH) remains a devastating cerebrovascular disease [<span class="CitationRef"><a href="#CR1">1</a></span>] and should be treated as a systemic disorder needing intensive care, not merely as an intracranial disorder, especially in poor-grade SAH patients [<span class="CitationRef"><a href="#CR2">2</a></span>]. Aging and poorer admission clinical grade are the most important predictors of poor outcomes [<span class="CitationRef"><a href="#CR3">3</a></span>]. In our recent series treated with early aneurysmal obliteration by endovascular coiling or surgical clipping, SAH patients over age 75 had 3-month modified Rankin scales 3–6 (poor outcomes) in 73.1% of cases with admission World Federation of Neurological Surgeons (WFNS) grades I<strong class="EmphasisTypeBold">–</strong>III and in 77.4% of cases with admission WFNS grades IV<strong class="EmphasisTypeBold">–</strong>V (poor grade), while SAH patients under age 75 had 3-month poor outcomes only in 13.1% of cases with admission WFNS grades I<strong class="EmphasisTypeBold">–</strong>III but still in 59.3% of cases with admission WFNS grades IV<strong class="EmphasisTypeBold">–</strong>V (unpublished data). All acute SAH patients with &gt; 10mm<sup>2</sup> ischemic brain lesion on diffusion-weighted magnetic resonance imaging or prolonged mean transit time &gt; 6.385 s in the whole brain on computed tomography perfusion may have irreversible brain damage and resulted in poor outcomes irrespective of any treatment including cerebrospinal fluid drainage and decompressive craniectomy to control intracranial pressure in addition to early aneurysmal obliteration [<span class="CitationRef"><a href="#CR4">4</a></span>, <span class="CitationRef"><a href="#CR5">5</a></span>]. The other patients with WFNS grade V had poor outcomes in 70<strong class="EmphasisTypeBold">–</strong>80%, even though the maximal treatment was undergone [<span class="CitationRef"><a href="#CR4">4</a></span><strong class="EmphasisTypeBold">–</strong><span class="CitationRef"><a href="#CR6">6</a></span>]; however, it should be noticed that no treatment caused poor outcomes in all grade V patients [<span class="CitationRef"><a href="#CR6">6</a></span>]. There are poor evidence and no guidelines available for the treatment of poor-grade SAH patients.
neurosciences,clinical neurology
What problem does this paper attempt to address?